Skip to main navigation
logo
  • English
  • Français

IR Navigation

  • Overview
  • News
  • Events & Presentations
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials
    • SEC Filings
    • AMF Regulated Information
    • Financial and extra-financial reports
    • Shareholders Meeting
    • Financial Calendar
    • General Meeting of OCEANE holders on March 10, 2025
  • Governance
    • Corporate Governance Overview
    • Executive Commitee
    • Board of Directors
    • Corporate Governance Documents
  • Resources
    • Shareholders Letter & Information
    • Email Alerts
    • Contact IR

Press Releases

Press Releases

07 Apr 2026
GENFIT Announces Publication of the 2025 Universal Registration Document  
02 Apr 2026
GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update  
09 Mar 2026
GENFIT Receives FDA Orphan Drug Designation for NTZ for the treatment of ACLF    
26 Feb 2026
GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update  
12 Feb 2026
GENFIT to receive US$20M milestone after Ipsen’s Iqirvo® exceeds the US$200M threshold in its first full year of net sales  
13 Jan 2026
GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
07 Jan 2026
GENFIT Announces 2026 Financial Calendar
06 Jan 2026
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N  

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • Contact IR

GENFIT Headquarters
Parc Eurasanté 885, Avenue Eugène Avinée 59120 Loos France GENFIT Corp
185 Alewife Brook Parkway, #210 Cambridge, MA 02138 VERSANTIS AG
Technoparkstrasse 1, 8005 Zürich, Suisse

     All rights reserved.